Global Research Landscape and Trends of Lung Cancer Immunotherapy: A Bibliometric Analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 19

PMID 36532038

Authors

Yanhao Liu

Xu Cheng

Xiaona Han

Xi Cheng

Shu Jiang

Yaru Lin

Zhen Zhang

Linlin Lu

Baozhen Qu

Yuxian Chen

Xiaotao Zhang

Affiliations

Soon will be listed here.

Abstract

background: Immunotherapy for lung cancer has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer immunotherapy.

Method: On 1 July, 2022, the authors identified 2,941 papers on lung cancer immunotherapy by the Web of Science and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top papers) as well as major journals on lung cancer immunotherapy. After that, recent research hotspots were analyzed based on the latest publications in major journals.

Results: These 2,941 papers were cited a total of 122,467 times. "Nivolumab vs. docetaxel in advanced non-squamous non-small-cell lung cancer" published in 2015 by Borghaei H et al. was the most cited paper (5,854 citations). Among the journals, was most influential. Corresponding authors represented China took part in most articles (904) and papers with corresponding authors from the USA were most cited (139.46 citations per paper). Since 2015, anti-PD-(L)1 has become the hottest research area.

Conclusions: This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on thousands of publications, and further suggests future research directions. Moreover, the results can benefit researchers to select journals and find potential collaborators. This study can help researchers get a comprehensive impression of the research landscape, historical development, and recent hotspots in lung cancer immunotherapy and provide inspiration for further research.

Citing Articles

Mapping the evolution and frontiers of : a bibliometric analysis and literature review.

Li C, He A, Hu J, Xia Y, He C, Zhuang W Transl Lung Cancer Res. 2025; 13(12):3764-3777.

PMID: 39830776 PMC: 11736581. DOI: 10.21037/tlcr-24-653.

Mesenchymal stem cell therapy in atherosclerosis: A bibliometric and visual analysis.

Cheng X, Li Y, Wang H, Zhang R, Fan K, Qi X World J Stem Cells. 2024; 16(12):1062-1085.

PMID: 39734478 PMC: 11669984. DOI: 10.4252/wjsc.v16.i12.1062.

The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis.

Zheng Y, Chen L, Liu X, Li R, Lei H, Chen G Front Oncol. 2024; 14:1428307.

PMID: 39588305 PMC: 11586257. DOI: 10.3389/fonc.2024.1428307.

Global research and current trends on nanotherapy in lung cancer research: a bibliometric analysis of 20 years.

Singh P, Semwal P, Gargi B, Painuli S, Aschner M, Alsharif K Discov Oncol. 2024; 15(1):539.

PMID: 39384612 PMC: 11465009. DOI: 10.1007/s12672-024-01332-2.

Research trends on cancer neuroscience: a bibliometric and visualized analysis.

Ma X, Deng K, Sun Y, Wu M Front Neurosci. 2024; 18:1408306.

PMID: 39268034 PMC: 11390534. DOI: 10.3389/fnins.2024.1408306.

References

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter H . Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase.... Lancet Oncol. 2019; 20(7):924-937. DOI: 10.1016/S1470-2045(19)30167-6. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H . Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol. 2022; 13:862084. PMC: 9044908. DOI: 10.3389/fimmu.2022.862084. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

10.

Liu Y, Jiang S, Lin Y, Yu H, Yu L, Zhang X . Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis. Front Oncol. 2022; 12:1066557. PMC: 9685815. DOI: 10.3389/fonc.2022.1066557. View

11.

Rodriguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E . Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021; 32(7):881-895. DOI: 10.1016/j.annonc.2021.04.008. View

12.

Giaccone G, Bazhenova L, Nemunaitis J, Tan M, Juhasz E, Ramlau R . A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015; 51(16):2321-9. DOI: 10.1016/j.ejca.2015.07.035. View

13.

Zhao Z, Yang C, Chen S, Yu H, Lin Y, Lin Y . Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021; 10(1):1996000. PMC: 8547836. DOI: 10.1080/2162402X.2021.1996000. View

14.

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G . Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022; 23(6):739-747. DOI: 10.1016/S1470-2045(22)00224-8. View

15.

Arrieta O, Barron F, Ramirez-Tirado L, Zatarain-Barron Z, Cardona A, Diaz-Garcia D . Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(6):856-864. PMC: 7290397. DOI: 10.1001/jamaoncol.2020.0409. View

16.

Kokol P, Blazun Vosner H . Historical, descriptive and exploratory analysis of application of bibliometrics in nursing research. Nurs Outlook. 2019; 67(6):680-695. DOI: 10.1016/j.outlook.2019.04.009. View

17.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

18.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

19.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

20.

Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A . SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021; 39(26):2872-2880. DOI: 10.1200/JCO.21.00276. View